How to Invest in Biotech Stocks — Everything You Need to Know


Biotech is notoriously risky. The odds of a drug getting FDA approval are staggeringly low, and even then companies aren’t in the clear. Investors might just think biotech is just way too risky to bother with… but it doesn’t have to be.

In this week’s episode of Industry Focus: Healthcare, host Shannon Jones and Motley Fool contributor Brian Feroldi share three methods that can get you exposure to biotech-style gains without taking on so much of that going-to-zero-overnight risk. Listen in to hear the pros and cons to investing in sector-wide ETFs, contract research organizations, and picks and shovels plays — plus, of course, some companies to add to your watchlist in each of those categories.
Subscribe to The Motley Fool’s YouTube Channel:
Or, follow our Google+ page:

Inside The Motley Fool: Check out our Culture Blog!
Join our Facebook community:
Follow The Motley Fool on Twitter:



Robert Dunfee


  1. Betsy Garcia
    July 19, 2021 at 11:16 am

    Yes yes yes I love it put I don't know how to get in it I have a brokerage account I just don't know where to go to get the stocks

  2. Betsy Garcia
    July 19, 2021 at 11:16 am

    Well the past two months I've been trying to buy biotech stocks I'm also a member of Brownstone I've been looking and trying to get biotech stocks for the past 2 months please help me

  3. viktor blazhevski
    July 19, 2021 at 11:16 am

    Please give my smarter brain. I am a kid in investing, which platform should I use to buy bio technology stocks

  4. Loyd Smith
    July 19, 2021 at 11:16 am

    Biotech is the future …

  5. Scott Postma
    July 19, 2021 at 11:16 am

    How in the world is this a video about how to invest in biotechs?? All you did is list biotech companies you like to invest in. You need to retitle the video.

  6. Lost Time
    July 19, 2021 at 11:16 am

    To track biotechs and pharmaceuticals, some good sites are and

  7. Clive Evrall
    July 19, 2021 at 11:16 am

    Suggest you check out Synairgen. Tiny uk company with treatment for Copid under test. A small shareholder.

  8. Toro Montana
    July 19, 2021 at 11:16 am

    What do you get when you mix biotech stonks with wallstreetbets?

  9. mike martin
    July 19, 2021 at 11:16 am

    You all should consider looking into Agenus (Agen). The company has been around since 2011. They’ve had a rocky road in the last but they now have gotten it together.

    They’re an immuno-therapy company but they also produce cell therapy (INKT’S), through their subsidiary company Agentus and they also produce vaccines.

    They also have the most powerful adjuvant (QS-21) on the market.

    Their main product and near future revenue generators are their PD-1 and CTLA-4 CPMS. Both are currently fast tracked for second line cervical cancer and have currently initiated a rolling BLA submission. Projected revenue for the drugs will be around ~165M domestically only. They have also partnered with a chinese pharma company called Betta pharmaceuticals for international rights in greater China. Agenus will be receiving milestone and royalty payments accordingly. Expansion of these two drugs will yield higher revenue. They’re also looking into partnering in Europe. Projected domestic and international revenue could be significantly higher than the ~165m I quoted for domestic sales.

    However, the biggest product they may have could be a potential multi blockbuster which is their next generation CTLA-4 1181. This is what most investors are banking on. It’s currently in phase 1 and showing very promising results. Ctla-4 is notorious for being toxic but agenus has manufacturing a very tolerable version that has low toxicity levels. This is huge.

    I believe they have 10 CPMS in the clinic and somewhere around 10 in preclinical. They have partnerships with GILEAD, MERCK, GLAXOSMITHKLINE, INCYTE AND BETTA PHARMACEUTICALS.
    I’ve mentioned most of the pros on the company. The only con is, they need capital to market the product once approved and for label expansion.

    They may need to dilute or continue to do what they’ve been doing successfully which is partnering up with someone for a cash injection. But dilution at this stage may be looked at in a positive light considering their active pipeline. I hope you all enjoyed my synopsis. GLTA!!

  10. Sly Badger
    July 19, 2021 at 11:16 am

    Interesting, but most of these stocks are now bubbles, with P/E at 250 or so. 2020 is madness.

  11. Wall Street Sizing Up
    July 19, 2021 at 11:16 am

    Thanks for sharing this video. I know something about Biotech. Biotechnology is a broad area of biology, involving the use of living systems and organisms to develop or make products. Depending on the tools and applications, it often overlaps with related scientific fields.

  12. Neto Lawrence
    July 19, 2021 at 11:16 am

    Thank you

  13. Nathan Allen
    July 19, 2021 at 11:16 am

    Biotech stock prices skyrocketed during the quarantine!!!

  14. Ricardo Grandío
    July 19, 2021 at 11:16 am

    wow, good advisor.

  15. Birdtube
    July 19, 2021 at 11:16 am


  16. Itchy Palms
    July 19, 2021 at 11:16 am

    Great video!

  17. Alex Cashman
    July 19, 2021 at 11:16 am


  18. killoreo
    July 19, 2021 at 11:16 am

    Why are ROE on biotech companues so negative (-) ??? Ex: SRPT(-75.87) or BLUE (-41.20). Yet people have made so much money off them in past couple of years??? I dont get it.

  19. Максим К
    July 19, 2021 at 11:16 am

    Really informative! Thanks! I'm looking forward new videos like this

  20. Alpha Bravo
    July 19, 2021 at 11:16 am

    Buddy is definitely using his ps4 headset lol

  21. Vinod Singaravelu
    July 19, 2021 at 11:16 am

    Thank you. Good content. Would be good to list the stock tickers at the end for the companies discussed in the podcast.

  22. suman c
    July 19, 2021 at 11:16 am

    Excellent content. Thank you

  23. Mr.Q
    July 19, 2021 at 11:16 am

    If you play the video at 2x speed she has autotune, its great!!!!!